Shattuck Labs Inc (STTK)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$6.79-2.44%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — reduce net losses per share: FY27 EPS -$0.52 vs target >-$0.40.
Shattuck Labs is advancing therapies for cancer and autoimmune diseases. The company maintains cash flow through recent $75M stock offering. It has shown earnings beats and stable execution. The stock has gained 51% over 21 days, signaling improving investor interest.
Shattuck Labs is loss-making with no revenue growth expected next year. Analysts forecast about -60% revenue decline. The company relies on dilutive stock offerings to fund operations. Market concerns about dilution pressure the stock.
The market prices in about -60% revenue decline and expects continued losses. The stock trades slightly below our model's value but well below the Street median. Our view is more cautious on growth and profitability prospects.
Breaks if: no successful capital raises of at least $75M within next 12 months
Breaks if: EPS loss worsens beyond -$0.50 per share next 12 months
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making but is focused on advancing its clinical trials, which could drive future growth.
The market appears to price in a low level of confidence, as indicated by the unjustified premium compared to peers. There is an expectations gap, suggesting that investors may not fully recognize the potential upside from the company's ongoing projects.
Management has shown stability and is on track with key clinical trials, although recent financial performance has been weak. The near-term risk is elevated, but the probability of missing expectations is relatively low.
The thesis hinges on the outcomes of clinical trials and the overall performance of the healthcare sector. Key triggers include guidance updates and sector performance from leading companies, which could impact sentiment and expectations.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified at this time.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: revenue decline exceeds 10% next 12 months
In the next 1 to 3 years, STTK's performance will depend on its clinical progress and sector dynamics. Not investment advice.